Neurochem Will Resubmit Kiacta After Conducting New Phase III Study
This article was originally published in The Pink Sheet Daily
Executive Summary
Company pulls NDA for AA amyloidosis therapy, currently "approvable" at FDA, while it conducts a new trial.